机构:[1]State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Department of Pulmonary and Critical Care Medicine, Guangzhou, China[2]Guangzhou Laboratory, Jinyintan Hospital, Wuhan, China[3]Department of Tuberculosis and Respiratory Disease, Jinyintan Hospital, Wuhan, China[4]Department of Nosocomial Infection Management, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China[5]Department of Critical Care Medicine, The First Affiliated Hospital of Zhejiang University, Hangzhou, China浙江大学医学院附属第一医院[6]Department of Critical Care Medicine, Zhongshan Hospital Fudan University, Shanghai, China[7]Department of Critical Care Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China首都医科大学宣武医院[8]Department of Critical Care Medicine, Zhongda Hospital, Southeast University, Nanjing, China[9]Emergency Department, 900th Hospital of Joint Service Corps of Chinese PLA, Fuzhou, China[10]Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[11]Department of Tuberculosis, Wuhan Jinyintan Hospital, Wuhan, China[12]Department of Respiratory and Critical Care Medicine Wuhan Jinyintan Hospital, Wuhan, China[13]Department of Critical Care Medicine, Wuhan Jinyintan Hospital, Wuhan, China[14]Research Center for Translational Medicine, Wuhan Jinyintan Hospital, Wuhan, China[15]Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology and Wuhan Jinyintan Hospital, Chinese Academy of Sciences, Wuhan, China
Background: Since 2020 COVID-19 pandemic became an emergent public sanitary incident. The epidemiology data and the impact on prognosis of secondary infection in severe and critical COVID-19 patients in China remained largely unclear. Methods: We retrospectively reviewed medical records of all adult patients with laboratory-confirmed COVID-19 who were admitted to ICUs from January 18th 2020 to April 26th 2020 at two hospitals in Wuhan, China and one hospital in Guangzhou, China. We measured the frequency of bacteria and fungi cultured from respiratory tract, blood and other body fluid specimens. The risk factors for and impact of secondary infection on clinical outcomes were also assessed. Results: Secondary infections were very common (86.6%) when patients were admitted to ICU for >72 hours. The majority of infections were respiratory, with the most common organisms being Klebsiella pneumoniae (24.5%), Acinetobacter baumannii (21.8%), Stenotropbomcmas maltopbilia (9.9%), Candida albicans (6.8%), and Pseudomonas spp. (4.8%). Furthermore, the proportions of multidrug resistant (MDR) bacteria and carbapenem resistant Enterobacteriaceae (CRE) were high. We also found that age >= 60 years and mechanical ventilation >= 13 days independently increased the likelihood of secondary infection. Finally, patients with positive cultures had reduced ventilator free days in 28 days and patients with CRE and/or MDR bacteria positivity showed lower 28-day survival rate. Conclusions: In a retrospective cohort of severe and critical COVID-19 patients admitted to ICUs in China, the prevalence of secondary infection was high, especially with CRE and MDR bacteria, resulting in poor clinical outcomes.
基金:
This work was supported by Emergency Key Program of Guangzhou Laboratory [Grant No. EKPG21- 17], The Natural Science Foundation of Guangdong Province, China [2020A1515011459], The Major special projects of the Ministry of Science and Technology [2020YFC0841300] and National Natural Science Foundation of China [81970071 and 82070084].
第一作者机构:[1]State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Department of Pulmonary and Critical Care Medicine, Guangzhou, China[2]Guangzhou Laboratory, Jinyintan Hospital, Wuhan, China
共同第一作者:
通讯作者:
通讯机构:[1]State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Department of Pulmonary and Critical Care Medicine, Guangzhou, China[14]Research Center for Translational Medicine, Wuhan Jinyintan Hospital, Wuhan, China[15]Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology and Wuhan Jinyintan Hospital, Chinese Academy of Sciences, Wuhan, China[*1]State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Department of Pulmonary and Critical Care Medicine, 151 Yanjiang Road, Guangzhou 510120, China.[*2]Wuhan Jinyintan Hospital, Research Center for Translational Medicine, Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology and Wuhan Jinyintan Hospital, Chinese Academy of Sciences, 1 Yintan Road, Dongxihu District, Wuhan 430023, Hubei, China.[*3]State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Department of Respiratory Medicine, 151 Yanjiang Road, Guangzhou 510120, China.[*4]State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Department of Pulmonary and Critical Care Medicine, 151 Yanjiang Road, Guangzhou 510120, China.
推荐引用方式(GB/T 7714):
Ling Sang,Yin Xi,Zhimin Lin,et al.Secondary infection in severe and critical COVID-19 patients in China: a multicenter retrospective study[J].ANNALS OF PALLIATIVE MEDICINE.2021,10(8):8557-8570.doi:10.21037/apm-21-833.
APA:
Ling Sang,Yin Xi,Zhimin Lin,Ying Pan,Bin Song...&Yimin Li.(2021).Secondary infection in severe and critical COVID-19 patients in China: a multicenter retrospective study.ANNALS OF PALLIATIVE MEDICINE,10,(8)
MLA:
Ling Sang,et al."Secondary infection in severe and critical COVID-19 patients in China: a multicenter retrospective study".ANNALS OF PALLIATIVE MEDICINE 10..8(2021):8557-8570